AlphAIAlphAI — Financial news for AI agents
Stock Titan$SWAG

Stran & Company (NASDAQ: SWAG) sets March 26 call on 2025 results

Stran & Company (NASDAQ: SWAG) has scheduled a conference call for March 26, 2026, at 10:00 A.M. Eastern Time to discuss its financial results for the 2025 fiscal year. Investors can access the call via telephone or webcast, with replays available through March 26, 2027, for webcasts and April 9, 2026, for telephone. The company also filed a Form 8-K announcing this event, which includes forward-looking statements regarding its financial performance and business strategies.

Original reporting
Stock Titan
Published Mar 23, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 23, 2026, 1:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Stran & Company (NASDAQ: SWAG) sets March 26 call on 2025 results — source image
Source · Stock Titan
Decision brief

The 30-second read

$SWAGNeutralMed
01

Why it matters

The event's outcome could influence short-term trading strategies, especially if results deviate from analyst expectations.

02

Market read

Moderate relevance for traders focusing on small to mid-cap stocks or sector-specific investments.

03

What to watch

Market reaction may be influenced by broader economic conditions or sector trends not captured in the sentiment score.

Relevance 6/10Timing: High, as the event is scheduled for March 26, 2026.

Background

Stran & Company is scheduled to report its 2025 fiscal year results via a conference call, a routine but important event for investors.

Company-level read

Ticker impact

$SWAGNeutralMedium confidence
Context

The upcoming earnings call for Stran & Company (NASDAQ: SWAG) scheduled for March 26, 2026, is a significant event for investors interested in the company's financial performance.

Expected impact

Likely minimal immediate price movement; potential for increased volatility post-announcement depending on results.

Evidence & confidence

The neutral sentiment score and the nature of earnings calls generally lead to cautious trading. Without prior earnings surprises or guidance, significant price swings are less expected.

Market effects

Sector

Potential sector-wide impact if the earnings results differ significantly from expectations.

Regional

Limited regional impact unless the company's results influence broader market indices.

Global

Minimal, as the company appears to be a regional or sector-specific entity.

Counterpoint

What could challenge this read

If the company reports unexpectedly strong results, a sharp upward move could occur, making a long position advantageous.

Key entities

  • Company
    Stran & Company

    A company listed on NASDAQ, scheduled to announce its 2025 financial results.

Read at source← All news

Related articles

$SWAGMed

Stran & Company Reports 32% Increase in Third Quarter 2026 Gross Profit as Gross Margin Expands to 33.3%

Stran & Company, Inc. (SWAG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Stran & Company Reports 32% Increase in Third Quarter 2026 Gross Profit as Gross Margin Expands to 33.3% Nine-Month Net Income of $1.1 Million, an Improvement of $2.1 Million Over the Prior-Year Period Conference Call to be Held Wednesday, November 11, 2026 at 10:00

SEC EDGAR 8-K
$SWAGMed

Stran (SWAG) Q2 2026 Earnings Call Transcript

Stran (SWAG) reported Q2 2026 revenue of $33.4M, up 2.4% YoY. Stran segment revenue grew 6.9% YoY, while SLS segment revenue declined 6.5%. Gross profit increased 1.6% to $10.0M, with gross margin at 30.0%. Net income was $309K, down from $643K YoY. The company secured new contracts and improved SLS gross margin to 24.3%. Management expects public warrant expiration in Q4 2026.

fool.com
$SWAGMed

Stran & Company Reports $33.4 Million in Revenue and $0.6 Million in EBITDA for the Second Quarter of 2026

Stran & Company, Inc. (SWAG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Stran & Company Reports $33.4 Million in Revenue and $0.6 Million in EBITDA for the Second Quarter of 2026 Conference Call to be Held Wednesday, August 12, 2026 at 10:00 a.m. Eastern Time Quincy, MA / August 11, 2026 / Stran & Company, Inc. (“Stran” or the “Company”)

SEC EDGAR 8-K
$PALIMedAI 8/10

Palisade Bio doses first patient in ulcerative colitis trial

Palisade Bio (NASDAQ:PALI) dosed the first patient in its Phase 2b ASCENTRA-UC trial for ulcerative colitis. The company reported a Q3 2026 net loss of $14.6M, up from $2.9M in 2025. It has $113.6M in cash. The trial will enroll 204 patients, with results expected in Q4 2027. The company also plans a Phase 2a Crohn’s disease study, with enrollment starting in Q1 2027.

investing.com
$IRMMed

Jefferies raises Iron Mountain stock price target on data center growth

Jefferies raised its price target on Iron Mountain (IRM) to $137 from $135, citing data center growth as a key driver. The stock is currently at $110.78, down 5% in a week but up 36.7% year-to-date. Jefferies projects data centers will contribute 20% of revenue by 2029, supporting 10% annual AFFO growth. Iron Mountain reported Q3 2026 earnings of $0.64 per share, beating estimates, with revenue up 13% year-over-year.

investing.com
$NHPMedAI 9/10

NATIONAL HEALTHCARE PROPERTIES, INC. AND SUBSIDIARIES Unaudited Pro Forma Condensed Combined Financial Information

National Healthcare Properties, Inc. (NHP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 NATIONAL HEALTHCARE PROPERTIES, INC. AND SUBSIDIARIES Unaudited Pro Forma Condensed Combined Financial Information ( in thousands ) National Healthcare Properties, Inc. (including, as by context, National Healthcare Properties Operating Partnership, L.P. (the “OP”) a

SEC EDGAR 8-K